Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark
Citation Manager Formats
Make Comment
See Comments

Abstract
Objectives To estimate the nationwide population-based incidence, prevalence, and geographical distribution of neuromyelitis optica (NMO) spectrum disorder (NMOSD) in Denmark based on the 2015 International Panel for NMO Diagnosis (IPND) criteria.
Methods We conducted a multicentre, historically prospective study. Data were sourced from the Danish National Patient Registry, the Danish Multiple Sclerosis Registry, departments of neurology, and laboratories providing aquaporin-4 antibody test. Cases were selected based on the 2006 Wingerchuk and the 2015 IPND criteria and were individually validated by an expert panel.
Results We confirmed NMO in 30 cases (2006 criteria) and NMOSD in 56 cases (2015 IPND criteria) between 2007 and 2014. Defined by the 2006 criteria, the incidence of NMO was 0.029 per 100,000 person-years (95% confidence interval [CI] 0.014–0.051), and the prevalence (aged 16 years and older) was 0.566 per 100,000 (95% CI 0.370–0.830). Based on the 2015 IPND criteria, the incidence of NMOSD was 0.070 per 100,000 person-years (95% CI 0.046–0.102), and the prevalence (aged 16 years and older) was 1.09 per 100,000 (95% CI 0.808–1.440), without regional differences.
Conclusions Our estimates of incidence and prevalence are similar to other Caucasian population–based studies using the 2015 IPND criteria. We found no geographical clustering in Denmark.
Glossary
- Ab=
- antibody;
- AQP4=
- aquaporin-4;
- CBA=
- cell-based assay;
- CI=
- confidence interval;
- DMT=
- disease-modifying therapy;
- ICD-10=
- International Classification of Diseases, Tenth Revision;
- IPND=
- International Panel for Neuromyelitis Optica Diagnosis;
- MOG=
- myelin oligodendrocyte glycoprotein;
- MS=
- multiple sclerosis;
- NMO=
- neuromyelitis optica;
- NMOSD=
- neuromyelitis optica spectrum disorder;
- ON=
- optic neuritis;
- OUH=
- Odense University Hospital;
- RH=
- Neuroimmunology Laboratory at the Danish Multiple Sclerosis Center, Rigshospitalet, University of Copenhagen;
- SSI=
- Statens Serum Institute;
- TM=
- transverse myelitis
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
The Article Processing Charge was funded by The Danish Multiple Sclerosis Society.
- Received April 17, 2018.
- Accepted in final form August 28, 2018.
- Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Disputes & Debates: Rapid online correspondence
- Author response to Drs. Asgari & Flanagan
- Viktoria Papp, Neurologist, Department of Neurology, Aarhus University Hospital (Denmark)
- Zsolt Illes, Professor, Neurologist, Odense University Hospital; Institute of Clinical Research, University of Southern Denmark (Odense, Denmark)
- Melinda Magyari, Associate Professor, Neurologist, The Danish MS Center, Rigshospitalet, University of Copenhagen; The Danish MS Registry, Copenhagen University Hospital
- Nils Koch-Henriksen, Associate Professor, Neurologist, Department of Clinical Epidemiology, Clinical Institute, Aarhus University (Aarhus, Denmark)
- Jette Lautrup Frederiksen, Professor, Neurologist, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen (Glostrup, Denmark)
- Finn Sellebjerg, Professor, Neurologist, The Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, University of Copenhagen (Copenhagen, Denmark)
- Egon Stenager, Professor, Neurologist, Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark (Odense, Denmark)
- Thor Petersen, Associate Professor, Neurologist, Department of Neurology, Aarhus University Hospital (Denmark)
Submitted January 03, 2019 - Epidemiology of neuromyelitis optica spectrum disorder
- Nasrin Asgari, MD, PhD, Associate Professor, Consultant, Department of Regional Health Research, Department of Molecular Medicine, University of Southern Denmark (Denmark)
- Eoin P. Flanagan, MD, Associate Professor, Neurologist, Department of Neurology, Mayo Clinic (Rochester, MN)
Submitted December 10, 2018
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.